AZD 8309

Drug Profile

AZD 8309

Alternative Names: AZD8309

Latest Information Update: 27 Feb 2007

Price : $50

At a glance

  • Originator AstraZeneca
  • Class Antirheumatics
  • Mechanism of Action Chemokine receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Chronic obstructive pulmonary disease; Rheumatoid arthritis

Most Recent Events

  • 01 Feb 2007 Discontinued - Phase-I for Rheumatoid arthritis in United Kingdom (unspecified route)
  • 01 Feb 2007 Discontinued - Phase-I for Chronic obstructive pulmonary disease in United Kingdom (unspecified route)
  • 04 Aug 2004 Phase-I clinical trials in Chronic obstructive pulmonary disease (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top